The identification of inherited cancer syndromes through the genetic analysis of the two LBC male patients prompted us to offer a cascade genetic testing in both of these two families, in order to improve cancer prevention using dedicated breast and ovarian cancer surveillance protocol in the family members who are a carrier of the BRCA2 pathogenic variant and in breast and gastric cancer patients’ family members who are a carrier of the CDH1 pathogenic variant in agreement with the prevention guidelines of these syndromes (11, 12, 24). This evidence concerns the gene BRCA2 and ovarian cancer.